Haematologie und Onkologie Muenchen-Pasing MVZ GmbH
- Address
- lock Available on a paid plan
Haematologie und Onkologie München-Pasing MVZ GmbH
Haematologie und Onkologie München-Pasing MVZ GmbH is a specialized medical research center dedicated to advancing treatment options for patients with hematological malignancies. The center demonstrates particular expertise in rare and complex blood cancers, with a strong emphasis on innovative combination therapies and targeted treatment approaches.
- Waldenström's Macroglobulinemia research, investigating novel combination therapies including Carfilzomib with Ibrutinib, Venetoclax with Rituximab, and Bortezomib-based regimens
- Chronic lymphocytic leukemia and chronic myeloid leukemia studies, evaluating next-generation targeted agents such as Acalabrutinib and Asciminib
- Multiple myeloma and lymphoma trials, including advanced Hodgkin lymphoma treatment optimization and relapsed/refractory multiple myeloma combination strategies
- Myelodysplastic syndromes research, focusing on anemia management with novel erythroid maturation agents like Luspatercept
The center's research portfolio reflects a commitment to both treatment-naive and relapsed/refractory patient populations, with particular focus on improving efficacy while reducing treatment-related toxicity. Their clinical trials encompass comprehensive evaluation of progression-free survival, safety profiles, and quality of life outcomes, positioning them at the forefront of hematologic oncology research in the Munich region.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Universitaetsklinikum Ulm AöR1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Universitaetsklinikum Ulm AöR3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Haematologie und Onkologie Muenchen-Pasing MVZ GmbH
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2 | Celgene Corp. | Phase III | Not Recruiting | Jan 2023 | — |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 3 | Unknown | 2016-07-15 | 2025-03-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.